Annual report pursuant to Section 13 and 15(d)

Supplemental Cash Flow Information (Tables)

v2.4.0.8
Supplemental Cash Flow Information (Tables)
12 Months Ended
Dec. 31, 2013
Supplemental Cash Flow Elements [Abstract]  
Summary of Supplemental Cash Flow Information
Supplemental cash flow information is summarized as follows: 
  
For the years ended December 31,
(In thousands)
2013
 
2012
 
2011
Interest paid
$
3,407

 
$
945

 
$
726

Income taxes paid, net
$
1,321

 
$
575

 
$
338

RXi common stock received
$
12,500

 
$

 
$

Non-cash financing:
 
 
 
 
 
Shares issued upon the conversion of:
 
 
 
 
 
Series D Preferred Stock
$
24,386

 
$

 
$
1,742

3.00% convertible senior notes
$
20,839

 
$

 
$

Common Stock warrants, net exercised
$
815

 
$
7

 
$
1,155

Issuance of Common Stock, Common Stock
   options and warrants to acquire PROLOR
$
586,643

 
$

 
$

Issuance of capital stock to acquire:
 
 
 
 
 
OPKO Diagnostics
$

 
$

 
$
22,452

FineTech
$

 
$

 
$
17,717

Farmadiet
$
4,435

 
$
805

 
$

OURLab
$

 
$
32,888

 
$

OPKO Brazil
$
435

 
$

 
$

Cytochroma
$
146,902

 
$

 
$